Zimbabwe has rejected a significant US health deal valued at 367 million US dollars (272 million pounds) over five years due to Washington's demand for sensitive information.
This move came to light after a official document from December was disclosed, indicating that President Emmerson Mnangagwa deemed the agreement was "lopsided".
An official spokesman later explained that the United States was requesting health data for scientific study and commercial gain but was unwilling to guarantee the benefits from any future medical innovations.
"We are forced to start the challenging and unfortunate process of winding down our support in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont in a statement.
The US Embassy indicated the United States had donated more than $1.9bn in health funding to Zimbabwe during the past two decades.
A medical body in Zimbabwe has called for further talks to secure a deal acceptable to all parties so the nation's vital HIV treatment initiative can continue.
Broader Context
This rejection follows a similar situation in Kenya, where a court suspended a similar health funding agreement after concerns were raised about the safety of citizens' health data.
Since resuming office last year, US President Donald Trump has reduced overseas assistance and closed the US Agency for International Development (USAID).
The agency had administered aid for the US government, but Trump claimed its spending was "wasteful" and his administration was seeking direct bilateral agreements to boost openness and accountability.
As per reports, 16 nations in Africa have so far signed similar health pacts, constituting over $18.3bn of fresh investment.
Details of the Rejected Agreement
The money for Zimbabwe was intended to gone towards "combating HIV/Aids, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"We are confident this cooperation would have delivered significant advantages for the people of Zimbabwe, particularly the 1.2 million currently on HIV treatment through American-funded initiatives," Tremont said.
However, official spokesman Nick Mangwana said the proposed deal was "unequal".
"The proposal required Zimbabwe to provide its genetic material and health information for a long time, with no equivalent assurance of access to any scientific breakthroughs – like new medicines or tests – that could be developed from that shared data," he stated.
"Put simply, our country would supply the raw materials for medical research with no assurance that the resulting innovations would be available to our people if a future disease outbreak arise."
National Interest and International Frameworks
Mangwana further pointed out that the US's withdrawal from the global health body and its pursuit of one-on-one health agreements were disrupting structures already set up via the international organization.
Mangwana gave as an example its Pathogen Access and Benefit Sharing system created to manage potential pandemics.
"This framework is designed to ensure that when a nation contributes its samples, the benefits – such as medicines and cures – are distributed fairly, not monopolised solely by those with the capability to create them."
The government's concerns over the US deal "must not be interpreted as anti-American sentiment," he added.
"We encourage further dialogue with our US partners on how future collaboration could be structured in a way that honours the independence and interests of both nations."
Medical Community Reaction
A leading public health body said it acknowledged the government's concerns, but suggested that talks need to persist considering a large portion of the nation's HIV programmes relied on international support.
"In cases where technical issues exist, including those involving data governance or implementation frameworks, these can frequently be resolved via detailed discussion and negotiated safeguards," the group commented.
The halted deal emphasises the complex challenges between accepting crucial foreign assistance and protecting a country's data in an ever more data-driven world.